Optimizing Humana Stelara Prior Authorization Workflows

Understanding Stelara (Ustekinumab) and Humana's Coverage Context

Stelara, known generically as ustekinumab, is an IL-12/23 inhibitor indicated for conditions such as psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. As a high-cost specialty biologic, Stelara typically falls under rigorous prior authorization (PA) requirements. For Humana, a major carrier with a significant Medicare Advantage enrollment, coverage policies for ustekinumab align with standard medical necessity criteria, often referencing Humana-developed guidelines, MCG-based criteria, or NCCN compendium for oncology-related indications, while adhering to CMS National and Local Coverage Determinations for its Medicare Advantage plans.

Humana's Prior Authorization Submission Channels for Stelara

Humana employs distinct channels for medical and pharmacy benefit prior authorizations, critical for specialty drugs like Stelara. For medical benefit submissions, providers primarily utilize Availity Essentials, which serves as Humana's main provider portal for PA initiation, eligibility verification, and document submission. X12 278 transactions are also supported via clearinghouses. For pharmacy benefit specialty drugs, including those dispensed by mail-order or home-delivery, CenterWell Specialty Pharmacy manages these requests, with retail pharmacy PA routing through Humana's pharmacy benefit operation and electronic PA (ePA) partners like CoverMyMeds and Surescripts.

Key Considerations for Humana Stelara Prior Authorization

• **Medical vs. Pharmacy Benefit**: Confirm whether Stelara is covered under the medical or pharmacy benefit for the specific Humana plan, as this dictates the submission channel.
• **Documentation Requirements**: Ensure comprehensive clinical notes, lab results, and prior treatment history are submitted to substantiate medical necessity for the indicated condition.
• **Step Therapy & Quantity Limits**: Be prepared for potential step therapy requirements, where less costly alternatives must be trialed first, and adhere to any specified quantity limits.
• **Site-of-Care Policies**: For infused or administered Stelara, verify any site-of-care policies Humana may have that influence coverage.
• **Medicare Advantage Alignment**: For Humana MA plans, ensure submitted criteria align with applicable CMS National and Local Coverage Determinations, as MA plans cannot impose more restrictive criteria than Original Medicare.

Common Denial Reasons and Appeal Pathways for Stelara with Humana

Denials for Stelara prior authorizations from Humana often stem from insufficient documentation, failure to meet medical necessity criteria, non-adherence to step therapy protocols, or site-of-service mismatches. For Medicare Advantage members, denials may also occur if the request conflicts with NCD/LCD guidelines. Humana outlines its appeal pathways in its provider manual and on its provider site. For Medicare Advantage, a five-level appeal structure (reconsideration, IRE, ALJ, MAC, judicial review) is mandated by CMS. Commercial appeals follow distinct pathways, with peer-to-peer reviews and expedited appeals available across lines of business.

Electronic PA and Turnaround Times for Humana Specialty Drugs

Humana is an impacted payer under CMS-0057-F, which mandates phased compliance for electronic prior authorization (ePA) and tightened turnaround times for Medicare Advantage. This means standard PA decisions for MA must be rendered within 7 calendar days, and expedited decisions within 72 hours, with full electronic API conformance by 2027. While Humana participates in the HL7 Da Vinci Project, specific production conformance for PAS, CRD, and DTR requires verification. For pharmacy benefit drugs like Stelara, ePA is often facilitated through partners like CoverMyMeds and Surescripts.